| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10221276 | The Journal of Arthroplasty | 2018 | 39 Pages |
Abstract
Strong evidence supports the efficacy of TXA to decrease blood loss and the risk of transfusion after primary TKA. No TXA formulation, dosage, or number of doses provided clearly improved blood-sparing properties for TKA. Moderate evidence supports preincision administration of IV TXA to improve efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Yale A. MD, Dipak B. MD, David S. MD, MBA, Adolph J. MD, Peter MPH, Kyle MPH, Stefano A. MD, Henry D. MD, Emil MD, Rebecca L. MD, Stavros G. MD, PhD, Siraj A. MD, Alexander P. MD, Craig J. MD,